-
Trelagliptin, RUNX2, and Osteoblastic Differentiation
2026-09-21
The reference study identifies an unexpected bone-forming effect of the DPP-4 inhibitor trelagliptin in MC3T3-E1 osteoblastic cells and links this response to increased RUNX2 through AMPK signaling. Its findings provide a mechanistic basis for further osteoporosis research while highlighting the need for validation in primary cells, animal models, and clinical studies.
-
AG-490: A Causal Probe for JAK2/STAT6
2026-09-20
AG-490, also called Tyrphostin B42, is a valuable pharmacological probe for testing JAK2/STAT6-dependent macrophage remodeling in hepatocellular carcinoma models. This article focuses on assay design, pathway attribution, and how to interpret AG-490 responses alongside exosomal SNORD52 biology.
-
RepSox: ALK5 Signaling for iPSC Assays
2026-09-19
RepSox is a potent and selective ALK5 inhibitor with applications spanning induced pluripotent stem cell reprogramming and TGF-β pathway research. This article develops a stage-specific framework for evaluating RepSox alongside optimized iPSC-derived megakaryocyte and platelet workflows, while separating demonstrated evidence from testable hypotheses.
-
Lisinopril Dihydrate: Reading ACE Assays
2026-09-18
Lisinopril dihydrate is a long-acting ACE inhibitor whose value in cardiovascular and renal research depends on more than its nanomolar potency. This article shows how to distinguish direct ACE target engagement from neighboring peptidase activity and downstream renin–angiotensin system effects.
-
Cap-Independent Translation of Linear mRNA
2026-09-18
The reference study introduces azide-modified dinucleotide priming followed by click-chemistry modification to improve the stability and protein output of cap-independent linear mRNAs. Its results support cap-independent translation as a tractable research and therapeutic strategy while providing chemical tools for studying transfection and translation in cells.
-
T7 RNA Polymerase for Reliable RNA Workflows
2026-09-17
Build precise in vitro transcription workflows with a promoter-specific enzyme that accepts both linearized plasmids and PCR templates. This guide connects template design, RNA synthesis, assay QC, and lessons from genome-wide editing studies to practical research decisions.
-
ddhCTP: Reliable Antiviral RNA Assay Design
2026-09-17
A scenario-driven guide to using ddhCTP (3ʹ-deoxy-3′,4′-didehydro-CTP) in cell-based antiviral and viability workflows. It explains how SKU B8293 supports mechanistic interpretation, controlled handling, and more defensible vendor selection.
-
Taltirelin Acetate: Itch & Neuroprotection Workflows
2026-09-16
Taltirelin acetate supports distinct preclinical workflows spanning acute and chronic itch, dopaminergic neuroprotection, sleep-related research, and formulation studies. This guide translates the latest mouse itch findings into practical assay design, dosing, controls, and troubleshooting strategies.
-
AG-490 and the JAK2/STAT6 Translational Gap
2026-09-16
AG-490, also known as Tyrphostin B42, offers a pharmacologic route to test whether exosomal SNORD52-driven macrophage polarization depends on JAK2/STAT6 signaling in hepatocellular carcinoma. This thought-leadership article connects the anchor study with practical assay design, pathway controls, competitive positioning, and translational decision-making while clearly distinguishing evidence from hypothesis.
-
Thioredoxin Control of CHK1 Inhibitor Sensitivity
2026-09-15
The 2024 Nature Communications study identifies thioredoxin 1 as a determinant of CHK1 inhibitor sensitivity in non-small cell lung cancer by connecting redox recycling of RRM1 with deoxynucleotide availability. Its findings support a mechanistically grounded combination strategy in which thioredoxin reductase inhibition enhances replication stress and CHK1 inhibitor activity, while also highlighting the need for biomarker-guided development.
-
LGMN Editing with Cas9 mRNA Restrains Metastasis
2026-09-15
The reference study integrates lipid nanoparticle delivery of Cas9 mRNA and guide RNA with LGMN disruption to examine breast cancer metastatic behavior. Its comparison of guide RNA transcription templates and use of functional lysosomal, cellular, and in vivo readouts provide a practical framework for evaluating RNA-based CRISPR workflows.
-
Aptamer-Targeted LNPs Deliver PTEN mRNA
2026-09-14
The reference study developed a PD-L1 DNA aptamer-conjugated lipid nanoparticle for selective PTEN mRNA delivery to castration-resistant prostate cancer cells. Its findings connect ligand-directed uptake with PTEN restoration, PI3K/AKT pathway suppression, apoptosis, and reduced xenograft growth, while also highlighting the characterization needed to translate targeted mRNA delivery.
-
iPSC-Based Trial Selection for Ultrarare Diseases
2026-09-14
Sequiera et al. developed a patient-specific iPSC platform to evaluate treatment candidates for an ultrarare Leigh-like syndrome caused by previously uncharacterized ECHS1 variants. The study shows how disease modeling, comparative drug screening, and longitudinal metabolic monitoring can reduce uncertainty before clinical trial enrollment.
-
RESTRICT-seq Maps KAT6A/B Dependencies in SCC Resistance
2026-09-13
The bioRxiv preprint introduces RESTRICT-seq, a time-gated CRISPR screening strategy designed to distinguish genes required for initial tumor-cell growth from those that sustain resistance after treatment or environmental selection. Its identification of KAT6A and KAT6B as epigenetic dependencies in squamous cell carcinoma resistance provides a rationale for temporally resolved validation of chromatin regulators in cancer biology research.
-
VZV Glycoprotein E Mutations and mRNA Vaccine Efficacy
2026-09-12
Cao and colleagues tested whether engineering the carboxyl-terminal trafficking region of varicella-zoster virus glycoprotein E could improve the immune performance of an LNP-formulated mRNA vaccine. Their comparison found that a C-terminal mutant produced consistently strong antibody and T-cell responses, supporting antigen trafficking as a rational design variable while stopping short of proving protective efficacy in infection or reactivation models.